ZBIO vs CHAD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZBIO Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Growth & Margin, Options & Structure while CHAD counters with relative strength in Momentum & Technical. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus CHAD at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against CHAD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZBIO | CHAD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | N/A | Larger Scale | ZBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | N/A | Higher Growth | ZBIO |
| Operating Margin (TTM) Profitability | -2747.5% | N/A | Higher Margin | ZBIO |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | ZBIO |
| Return on Equity (ROE) Capital Efficiency | -265.1% | N/A | Higher ROE | ZBIO |
| 52-Week Range Position Momentum | 46% ($14โ$45) | 100% ($7โ$10) | Stronger Trend | CHAD |
| Beta / 30D Volatility Risk Regime | 1.16ฮฒ ยท 59% Vol | 0.71ฮฒ ยท 11% Vol | Lower Realized Risk | CHAD |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 53.8 / 100 (HOLD) | Higher Composite | CHAD |